Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-06-10
2008-06-10
Saoud, Christine J. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S866000, C530S303000, C530S350000, C530S403000, C536S063000
Reexamination Certificate
active
07384915
ABSTRACT:
Novel chimeric fusion proteins comprising immunodominant epitopes of GAD and insulin are provided. Also provided are immunomodulatory methods for the use of such proteins for both the prevention and treatment of Type 1 diabetes mellitus. The chimeric fusion proteins of the invention are useful in predicting risk of onset of Type I diabetes, determining prognosis of Type 1 diabetes patients early in disease progression, and in evaluating patients for suitability as recipients of transplants of pancreatic cells or tissues. The administration of the proteins of the invention in accordance with the immunomodulatory methods of the invention results in beneficial effects on disease development and severity in patients suffering from or predicted to be at risk of developing Type 1 diabetes, as well as on the outcome of transplants of pancreatic cells or tissues in Type I diabetes patients.
REFERENCES:
patent: 4431740 (1984-02-01), Graeme et al.
patent: 4939094 (1990-07-01), Kuga et al.
patent: 5691448 (1997-11-01), Baekkeskov et al.
patent: 5821334 (1998-10-01), Powers
patent: 5998584 (1999-12-01), Baekkeskov et al.
patent: 0940470 (1999-09-01), None
patent: WO-96/26218 (1996-08-01), None
Abbas et al. Cell Mol. Immunol., 376-392. (1994).
Abo, S. et al. “Preparation of Highly Purified Human Myelin Oligodendrocyte Glycoprotein in Quantities Sufficient for Encephalitogenicity and Immunogenicity Studies.” Bio. Molec. Biol. Int., 30:945-958. (1993).
Adorini, L. et al. “Selective Immunosuppression.” Immunol. Today, 14:285-289. (1993).
Allegretta, M. et al. “Homologies Between T Cell Receptor Junctional Sequences Unique to Multiple Sclerosis and T Cells Mediating Experimental Allergic Encephalomyelitis.” (1994).
Allegretta, M. et al. “T Cells Responsive to Myelin basic Protein in Patients with Multiple Sclerosis.” Science, 247:718-722. (1990).
Alvord, E. et al. “Has Myelin Basic Protein Received a Fair Trial in the Treatment of Multiple Sclerosis?” Ann. Neurol., 6:461-468. (1979).
Ammerer. Meth. Enzymol. 101:192. (1983).
Amor, S. et al. “Identification of Epitopes of Myelin Oligodendrocyte Glycoprotein for the Induction of Experimental Allergic Encephalomyelitis in SJL and Biozzi AB/H Mice.” Journal of Immunology, 153:4349-4356. (1994).
Aruga, J. et al. “Identification of the New Isoforms of Mouse Myelin Basic Protein: The Existence of Exon 5a.”J. Neurochem, 56:1222-1226. (1991).
Atkinson and Maclaren. J. Clin. Invest. 92:1608-1616. (1993).
Atkinson et al. Diabetes, 39:933-937. (1990).
Atkinson et al. J. Clin. Invest. 91:350-356. (1993).
Atkinson et al. Lancet 335:1357-1360. (1990).
Atkinson et al. Lancet, 339:458-459. (1992).
Ausubel et al. Current Protocols in Molecular Biology, John Wiley & Sons, New York. (1994).
Baekkeskov et al. J. Clin. Invest. 79:926-934. (1987).
Baekkeskov et al. Nature 347:151-156. (1990).
Baekkeskov et al. Nature, 298:167-169. (1982).
Barnett, L. et al. “Enhancement of Autoimmune Disease Using Recombinant Vaccinia Virus Encoding Myelin Proteolipid Protein.” J. Neuroimmunol., 44:15-26. (1993).
Bishopp, F. “Autoimmune Stock Sinks on Disappointing Phase III Myloral Trial Data in MS.” Bioworld Today, 8(77):1. (1997).
Bock et al. Lancet, 339:1504-1506. (1992).
Boehme and Leardo. Eur. J. Immunol. 23:1552-1560. (1993).
Boehme, S. et al. “Propriocidal Apoptosis of Mature T Lymphocytes Occurs at S Phase of the Cell Cycle.” Eur. J. Immunol., 23:1552-1560. (1993).
Bonifacio et al. Lancet, 335:147-149. (1990).
Bowman et al. Immunol. Today 15(3):115-120. (1994).
Brunner et al. Nature, 373:441-444. (1995).
Butler et al. J. Exp. Med. 178:2097-2106. (1993).
Carnegie, P. et al. “Amino Acid Sequence of the Encephalitogenic Basic Protein.” Biochem. J., 123:57-67. (1971).
Chang et al. Nature, 275:615 et seq. (1978).
Chen, Y. et al. “Regulatory T Cell Clones Induced by Oral Tolerance: Suppression of Autoimmune Encephalomyelitis.” Science, 265:1237-1240. (1994).
Chiang, B. et al. “Prospects of Vaccination in Autoimmune Diseases.” Int. Arch. Allergy Immunol., 98:181-188. (1992).
Chou and Fasman. Adv. Enzymol. 47:45-147. (1978).
Chou, Y. et al. “Frequency of T Cells Specific for Myelin Basic Protein and Myelin Proteolipid Protein in Blood and Cerebrospinal Fluid in Multiple Sclerosis.” J. Neuroimmunol., 38:105-114. (1992).
Chou, Y. et al. “Specificity of Human T Cell Clones Reactive to Immunodominant Epitopes of Myelin Basic Protein.” J. Neurosci. Res., 28:280-290. (1991).
Chou. “Prediction of Protein Structure and the Principles of Protein Conformation.” Plenum Press, pp. 549-586. (1990).
Cohen et al. Ann Rev. Immunol. 10:267 et seq. (1992).
Coligen et al. Current Protocols in Immunology, John Wiley & Sons, NY. (1995).
Conrad et al. Nature, 371:351-355. (1994).
Correale, J. et al. “Patterns of Cytokine Secretion by Autoreactive Proteolipid Protein-Specific T Cell Clones During the Course of Multiple Sclerosis.” J. Immunology, 154:2959-2968. (1995).
Cotter et al. Anticancer Research, 10:1153 et seq. (1990).
Crispe. Immunity, 1:347-349. (1994).
Critchfield, J. et al. “T Cell Deletion in High Antigen Dose Therapy of Autoimmune Encephalomyelitis.” Science, 263:1139-1143. (1994).
Daniel et al. Proc. Natl. Acad. Sci. USA, 93:956-960. (1996).
Davis et al. Basic Methods in Molecular Biology, 2nd ed., Appleton and Large, Norwalk, CT. (1995).
De Aizpurua et al. Proc. Natl. Acad. Science USA, 89:9841-9845. (1992).
Dhein et al. Nature, 373:438-441. (1995).
Diehl, H. et al. “Individual exons encode the integral membrane domains of human myelin proteolipid protein.” Proc. Natl. Acad. Sci. USA, 83:9807-9811. (1986).
Duvall et al. Immunol. Today, 7:115-119. (1986).
Einstein et al. “The isolation from bovine spinal cord of a homogeneous protein with Encephalitgenic Activities.” Neurochem. 9:252-361. (1962).
Elliott et al. J. Clin. Invest., 98:1-11. (1996).
Endoh, M. et al. “DM-20, A Proteolipid Apoprotein, Is an Ecephalitogen of Acute and Relapsing Autoimmune Encephalomyelitis in Mice.” J. Immunol., 137:3832-3835. (1986).
Evans and Scarpulla. Gene, 84:135 et seq. (1989).
Falorni et al. Diabetologia, 39:1091-1098. (1996).
Farrell, Jr. RNA Methodolgies: A Laboratory Guide for Isolation and Characterization. Academic Press Inc., San Diego, CA. (1993).
Foster. Harrison's Principles of Int. Med, 13th Ed., McGraw-Hill, NY. pp. 1979-2000. (1994).
Fritz, R. et al. “Encephalitogenicity of Myelin Basic Protein Exon-2 Peptide in Mice.” J. Neuroimmunol., 51:1-6. (1994).
Garnier et al. J. Mol. Biol, 120:97-120. (1978).
Goeddel et al. Nucl. Acids Res., 8:4057 et seq. (1980).
Greer, J. et al. “Identification and Characterization of a Second Encephalitogenic Determinant of Myelin Proteolipid Protein (Residues 178-191) for SJL Mice.” J. Immunol., 149:783-788. (1992).
Griffin and Griffin. PCR Technology, Current Innovations, CRC Press, Boca Raton, FL. (1994).
Griffin et al. Am. J. Pathol., 147:845-857. (1995).
Grima, B. et al. “A Novel Transcript Overlapping the Myelin Basic Protein Gene.” J. Neurochem., 59:2318-2323. (1992).
Grosjean and Fiers. Gene, 18:199 et seq. (1982).
Hanninen et al. J. Clin. Invest., 90:1901-1910. (1992).
Harrison. Immunol. Today, 13:348-352. (1992).
Harwood, Ed. Protocols for Gene Analysis: Methods in Molecular Biology, vol. 31, The Humana Press, Totowa, NJ. (1994).
Hatfield et al. Diabetologia, 40:1327-1333. (1997).
Hernan, R. et al. “Human Hemoglobin Expression inEscherichia coli: Importance of Optimal Codon Usage.” Biochemistry, 31:8619-8628. (1992).
Herold et al. J. Exp. Med., 176:1107-1114. (1992).
Higgins, Paul et al. “Suppression of Experimental Autoimmune Encephalomyelitis by Oral Administration of Myelin Basic Protein and its Fragments.” J. Immunol., 140:440-445. (1988).
Ho et al. Gene, 77:51-59. (1989).
Honeyman et al
Matis Louis A.
Mueller John
Wang Yi
Alexion Pharmaceuticals, Inc.
Ropes and Gray LLP
Saoud Christine J.
LandOfFree
Chimeric insulin-gad proteins for treating patients with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric insulin-gad proteins for treating patients with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric insulin-gad proteins for treating patients with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2797581